Metacrine Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“In preclinical animal studies with our FXR agonist product candidates, we have observed statistically significant improvements in colon histology and at levels similar to that of a mouse antibody which targets IL12/23.” (Page 4) Read the full document
Metacrine, Inc. is a United States-based biotechnology company. The Company is engaged in developing therapeutics for metabolic diseases. The Company leverages approximately two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders. The Company focuses on advancing research in nuclear hormone receptors for treatment of metabolic diseases.
Company Website: https://metacrine.com